Impact of BMI on Survival Outcomes of Immunotherapyin Solid Tumors: A Systematic Review
Growing research has focused on obesity as a prognostic factor during therapy with immune-checkpoint inhibitors (ICIs). The role of body-mass index (BMI) in predicting response and toxicity to ICIs is not clear, as studies have shown inconsistent results and significant interpretation biases. We per...
Main Authors: | Alice Indini, Erika Rijavec, Michele Ghidini, Gianluca Tomasello, Monica Cattaneo, Francesca BarbinClaudia Bareggi, Barbara Galassi, Donatella Gambini, Francesco Grossi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/5/2628 |
Similar Items
-
Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series
by: Sarah Picard, et al.
Published: (2021-07-01) -
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01) -
A real‐world data of Immune checkpoint inhibitors in solid tumors from India
by: Vanita Noronha, et al.
Published: (2021-03-01) -
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
by: Philip Friedlander, et al.
Published: (2018-09-01) -
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Pierpaolo Correale, et al.
Published: (2020-08-01)